Mydecine: Psilocybin Sciences

<p>Today we have the pleasure of speaking with Josh Bartch, the CEO of Mydecine, a research &amp; development company with a special interest in psilocybin and psychoactive treatments. We discuss the origins of their work, their team, and current research and practices in the field.</p><p><b>Topics covered:</b></p><ul><li>Mydecine&apos;s mission and commitment to human benefit via fungal discovery</li><li>Psilocybin treatment for PTSD and other mental health concerns</li><li>Machine-learning based drug discovery</li><li>Formulation and commercialization of psychedelic therapeutics </li><li>The deficiencies in chemical compounds in psilocybe mushrooms</li><li>Varietals of psilocybin-containing mushrooms </li><li>Collaborative and intern opportunities at Mydecine’s facilities</li><li>Describing new compounds in functional mushrooms</li><li>Bureaucracy of importing and researching psychedelic mushrooms </li><li>Bioavailability of psilocybin </li><li>Managing ethical clinical research</li></ul><p><b>Show notes:</b></p><ul><li>Mydecine website: <a href='https://www.mydecine.com/'>https://www.mydecine.com/</a></li><li>Josh Bartch LinkedIn: <a href='https://www.linkedin.com/in/josh-bartch-a5361b96'>https://www.linkedin.com/in/josh-bartch-a5361b96</a></li><li>MindLeap app: <a href='https://mindleap.health/'>https://mindleap.health/</a></li></ul>